Takeda Pharmaceutical Co. $TAK Shares Bought by QRG Capital Management Inc.

Key Points

• QRG Capital Management Inc. increased its stake in Takeda Pharmaceutical Co. by 11.8% during the second quarter, holding a total of 432,654 shares now valued at $6.69 million.
• Takeda reported earnings per share of $0.52 for the last quarter, exceeding analyst expectations of $0.47, but its revenue was $7.45 billion, below the anticipated $7.96 billion.
• Current consensus ratings on Takeda Pharmaceutical's stock are mixed, with one analyst recommending a Buy, one a Hold, and another a Sell.

QRG Capital Management Inc. boosted its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 11.8% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 432,654 shares of the company's stock after acquiring an additional 45,726 shares during the quarter. QRG Capital Management Inc.'s holdings in Takeda Pharmaceutical were worth $6,689,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth about $37,000. Farther Finance Advisors LLC lifted its position in Takeda Pharmaceutical by 29.2% during the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after acquiring an additional 1,045 shares during the period. Fifth Third Bancorp lifted its position in Takeda Pharmaceutical by 85.5% during the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock worth $78,000 after acquiring an additional 2,411 shares during the period. GAMMA Investing LLC lifted its position in Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock worth $105,000 after acquiring an additional 1,296 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth about $125,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock opened at $14.62 on Monday. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.69. The business has a 50-day moving average price of $14.84 and a 200 day moving average price of $14.82. The firm has a market cap of $46.50 billion, a PE ratio of 48.72 and a beta of 0.21.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The firm had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Sell-side analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TAK shares. Weiss Ratings reiterated a "hold (c)" rating on shares of Takeda Pharmaceutical in a research note on Saturday, September 27th. Zacks Research lowered Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research note on Thursday, August 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Takeda Pharmaceutical has a consensus rating of "Hold".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.